Brightgene Bio-Medical Technology Co., Ltd.

BrightGene's Oral GLP-1/GIP Dual Agonist BGM0504 Shows Promising Weight Loss Results in Phase 1 Trials

- BrightGene reported positive Phase 1 results for BGM0504, an oral GLP-1/GIP dual receptor agonist, demonstrating weight reductions of 1.0% to 5.6% in China and 2.7% to 8.2% in the U.S. after 4-8 weeks of treatment. - The investigational drug was generally well tolerated across both studies with no serious adverse events, and gastrointestinal side effects were predominantly mild to moderate and transient. - BGM0504 achieved steady-state exposure after 2-3 weeks with dose-proportional pharmacokinetics, supporting once-daily oral dosing for obesity treatment. - The company is developing both oral and subcutaneous formulations, with the subcutaneous version already in Phase 3 trials as part of their broader metabolic disease strategy.